SUMMARY Simultaneous plasma dexamethasone and cortisol levels were followed at intervals over 8 hour periods on 40 occasions in 19 subjects who received regular high dosage dexamethasone therapy (rarely less than 12 mg a day) for various neurological and neurosurgical conditions. Lower dexamethasone doses (for example 2 mg daily for 2 days) normally suppress adrenal cortical production of cortisol to below 50 Ag/l for at least 8 hours. However, in 12 of the 35 studies that did not take place at the first steroid dose or in subjects taking second daily bolus steroid dosage such suppression was not present 8 to 12 hours after dexamethasone intake, though it was shown that dexamethasone could suppress cortisol production in all these cases. Failure of maintained suppression despite the high steroid dose appeared to be related to rapid elimination of dexamethasone. These findings may help explain the relative rarity of adrenal failure in clinical neurological practice after high dosage steroid therapy is ceased.
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Oral dexamethasone intake is sometimes used to suppress adrenal production of cortisol, as a test of control of the pituitary-adrenal axis. The administered glucocorticoid should act on the hypothalamus and pituitary to inhibit corticotropin formation, and this in turn should remove the stimulus for adrenal production of cortisol. The usual oral dexamethasone dose is 0*5 or 1.0 mg, given every 6 hours for 48 hours. The criterion of adrenal suppression is taken as a morning peak plasma cortisol level below 50 ,ug/l (138 nmol/l) These dexamethasone pharmacokinetic studies were carried out in volunteers who gave informed consent during the course of high dosage steroid therapy given for a variety of neurological or neurosurgical indications. The investigational protocol had received institutional ethics committee approval. Single oral or intravenous dexamethasone doses, nearly always equivalent to 4 mg of the base, were given, on almost all occasions between 8 and 10 am. The most recent dexamethasone dose had been taken 8-12 hours before, in nearly all instances. Forearm venous blood collections were carried out as near as possible to the following times in relation to the test dose of dexamethasone: 0, 0-16, 0-33, 0-50, 0-75, 1-0, 1-5, 2-0, 2-5, 3-0, 4-0, 5-0, 6-0 and 8-0 hours. Plasma dexamethasone and cortisol concentrations were measured in each blood sample, using the assay described below. Plasma steroid measurement The assay used was a modification of the high performance liquid chromatographic method originally described by Cham et al.5 With the modification it was possible to measure simultaneous plasma concentrations of dexamethasone and cortisol in each sample in a single assay run. After addition of 100 ,ul ethanolic cyheptamide (100 ug/ml), to serve as an internal standard, 3 ml plasma samples were made alkaline with NaOH and extracted with N-heptane. The organic phase was aspirated to waste, and the inorganic phase mixed with 300 mg NaCl and 100 ml dichloromethane. The organic phase was then separated off, evaporated to dryness, reconstituted in 50 pAl methanol and injected into a high performance liquid chromatography system comprising a Waters Associates M6000 A pump, a Bondapak C18 column, and a Waters Associates Model 440 absorbance detector set at a wavelength of 254 nm. The mobile phase used was a mixture of acetic acid 12 parts, butanol 75 parts, methanol 40 parts and water 873 parts, at room temperature and a flow rate of 2*5 ml/minute at a pressure of 23333 kPa. With this system retention times were, respectively 7*8, 13*4 and 16-5 minutes for cortisol, dexamethasone and cyheptamide. Quantitation was by the peak height ratio method.
Results
The typical time-courses of plasma dexamethasone and cortisol concentrations after an intravenous dose of dexamethasone given to a patient are shown in fig 1. As was nearly always the case, the time course of the cortisol levels lagged 1-2 hours behind the dexamethasone levels. The time-courses of these parameters in subject F, when measured on two occasions two months apart, are shown in fig 2 of dexamethasone in the interval between the two studies. Table 2 sets out, for each study in each subject, the plasma dexamethasone concentration present at the outset of the study (a residue from the previous dexamethasone dose), the peak plasma dexamethasone level attained in the study and its time of occurrence. This peak value, and the time at which it occurred, varied depending on whether the dexamethasone was given intravenously or orally. Table 2 .
In all 40 studies, the dexamethasone dose given produced a decrease in plasma cortisol levels, from a mean peak value of 63-7 + SD 64-6 ,g/l to a mean minimum value of 13 8 + 9-2 ,ug/l. The true depression in plasma cortisol levels may have been greater Cortisol production during high dose dexamethasone therapy in neurological and neurosurgical patients 1085 cortisol level in response to dexamethasone was below the 50 gg/l value that is taken as the criterion for suppression of cortisol production.
Either the initial, or the maximum, plasma cortisol concentration was above the 50,sg/l criterion in 15 of the 40 studies. Three of these studies had been carried out at the time of the first dexamethasone dose given to the subject, so that suppressed values would not be expected at this time. However in 12 studies, despite previous and continuing high dose dexamethasone therapy, maximum plasma cortisol concentrations ranged from 60 5 to 2046,tkg/l, with six of the maximum values exceeding 100 ,g/l. When reasons for these 12 apparent failures of suppression of cortisol production from previous dexamethasone dosage were sought the following points emerged: (1) all but one subject with maximum plasma cortisol levels above 50 ug/l had unmeasurably low plasma dexamethasone levels at the outset of study. The one exception (H2) had an initial dexamethasone level of only 8-3 ug/l. In contrast there were measurable plasma dexamethasone levels in 12 of the 24 studies in which plasma cortisol levels were below 50,4g/l throughout the study.
(2) two studies (R2 and S) were carried out in subjects receiving a second daily oral bolus dosage regime of 12 mg dexamethasone, and the last dexamethasone dose had been taken 48 hours before the study.
(3) in the remaining 10 studies (Bi, B2, F4, F5, H2, I1, L2, P1, Q1, Q2) mean dexamethasone half life was 1-60 + SD 1-37 hours while in the studies in which initial plasma cortisol levels were suppressed below 50 gg/l from the previous dexamethasone dose, mean dexamethasone half life was 4-57 + [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] hours, a statistically significant difference (t = 2-6666; p < 0.02).
(4) the mean times to achieve minimum suppressed plasma cortisol levels were similar (t = 0 5543, p < 0.60) in these same 10 studies (mean 6-0 + SD 1-85 hours), and in the studies in which initial cortisol suppression was present (mean 5-67 + SD 2-07 hours). However, minimum cortisol levels were statistically significantly higher (t = 3-2866; p < 0.005) in these 10 studies (mean 21-1 + SD 13*8 ,ug/l) than in the studies in which initial cortisol suppression had been present (mean 10.5 + SD 4 9 4f1).
Thus there appeared to be a correlation between shortened dexamethasone half lives and less complete suppression of cortisol production, both from the dexamethasone dose under study and from the previous dexamethasone dose.
Discussion
Not unexpectedly, the present study showed that the high dexamethasone doses often used in neurological and neurosurgical practice were capable of suppressing endogenous cortisol production and usually of maintaining the suppression for at least 6 to 8 hours in all 40 instances in which the phenomenon was studied. In the two subjects in whom dexamethasone was given in a single large bolus dose each 48 hours the investigation showed that cortisol suppression to some extent passed off between dexamethasone doses. This, of course, reflects in part the rationale for administering steroids in high dosage at rather long intervals. However, what was perhaps unexpected was that, in the 35 studies not carried out either at the time of the first dexamethasone dose or in the two persons receiving second daily bolus steroid therapy, there were 10 in which plasma cortisol levels were above the suppression criterion at the outset of study (some 8 to 12 hours after the most recent dexamethasone dose). Of these 10 studies, in six plasma cortisol values were within the physiological range for the variable (100-250 ug/l), though the values may still have been suppressed to some extent in relation to the affected individual's normal levels for the time of day. This relative failure to maintain suppressed cortisol production for as long as anticipated, in persons shown capable of such suppression in the present study, occurred with daily dexamethasone doses often 5 to 10 times greater than those (1-2 mg per day) known to suppress cortisol production for at least 8 hours in normal subjects. The key to this relatively incomplete suppression in some subjects may lie in the more rapid elimination of dexamethasone in the group whose cortisol production was less suppressed both from the dexamethasone dose under study, and from the previous dose. More than a decade ago Jubiz et al.6 showed that patients treated with phenytoin (resulting in a shortened dexamethasone half life) failed to achieve cortisol suppression with 2 mg dexamethasone daily doses, but did achieve suppression with doses of 8 mg daily. Meikle7 has demonstrated the importance of achieving a sufficient plasma dexamethasone level before concluding that adrenal cortical function cannot be suppressed in a given individual. The present investigation has also shown the phenomenon of decreased suppression in relation to shortened dexamethasone half-lives, though in this study even higher daily dexamethasone doses than those used by Jubiz et 
